Advances in Hematology最新文献

{"title":"Newly Diagnosed High-Risk Multiple Myeloma: Outcomes and Management.","authors":"Fatma Zehra Yasar, Elan Gorshein","doi":"10.1155/ah/6622365","DOIUrl":"10.1155/ah/6622365","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a heterogeneous hematologic malignancy, with high-risk cytogenetic abnormalities (HRCAs) such as del(17p), t(4; 14), t(14; 16), and gain(1q) contributing to poor prognosis in approximately 20%-25% of newly diagnosed patients. These abnormalities are associated with aggressive disease, frequent relapses, and inferior progression-free and overall survival. This review explores the evolving therapeutic landscape for high-risk MM, focusing on induction strategies for both transplant-eligible and transplant-ineligible patients, the role of autologous stem cell transplantation (ASCT), and the use of consolidation and maintenance therapies. Emerging modalities such as bispecific antibodies and chimeric antigen receptor T-cell (CAR-T) therapies are examined, particularly in the context of their integration into earlier lines of treatment. Quadruplet induction regimens incorporating proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies have shown promise in improving outcomes and are becoming a cornerstone of frontline therapy. The review also emphasizes the potential of personalized, risk-adapted approaches based on cytogenetic profiling and minimal residual disease (MRD) monitoring. Ongoing clinical trials investigating the early use of CAR-T cells and bispecific antibodies may further transform the standard of care for patients with high-risk MM.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"6622365"},"PeriodicalIF":0.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12494473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Typical Neutrophil Count With Fy(a-b-) Status Among Hematology Referrals for Neutropenia at an Urban Safety-Net Hospital.","authors":"Anya Parekh, Adam Lerner, Reggie R Thomasson, J Mark Sloan","doi":"10.1155/ah/2488148","DOIUrl":"10.1155/ah/2488148","url":null,"abstract":"<p><p><b>Background:</b> Duffy-null associated neutrophil count (DANC) causes neutropenia without clinical sequelae. 25%-50% of people of African ancestry in the United States are thought to have Fy(a-b-) status and are often erroneously identified as having pathologically low neutrophil counts. <b>Results:</b> We performed a retrospective chart review of new neutropenia referrals to the Hematology Clinic at Boston Medical Center (BMC) to evaluate diagnostic patterns for Fy(a-b-) status. 103 new referrals for neutropenia were made from 1/2020 to 2/2022, of which 78 were included for further analysis. DANC was the etiology for low neutrophil count in 64.1%, 82% of whom were African American or Black or were born in an African or Caribbean country. 66% of these patients underwent confirmatory blood bank testing, and 97% of patients tested were confirmed to have Fy(a-b-) status. The average cost of a laboratory visit for patients with typical neutrophil count with Fy(a-b-) status was on average lower, but not negligible, than those without ($363.82 vs. $737.93; <i>p</i> < 0.005). These patients were also statistically less likely to have a follow-up appointment (<i>p</i>=0.039). <b>Conclusions:</b> Expanded use of serological Fy(a,b) antigen testing for patients with chronic, asymptomatic neutropenia could reduce the cost of care and referrals to the hematology clinic.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"2488148"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematological Profiles of Adults Coinfected With HIV and Malaria Receiving Highly Active Antiretroviral Therapy at Bonga Gebretsadik Shawo General Hospital, Southwest Ethiopia: A Comparative Cross-Sectional Study.","authors":"Fikre Demango, Edosa Tadasa, Girum Tesfaye Kiya","doi":"10.1155/ah/3894305","DOIUrl":"10.1155/ah/3894305","url":null,"abstract":"<p><p><b>Background:</b> Malaria and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) are widely recognized infectious diseases that pose serious public health challenges in Sub-Saharan Africa and around the globe. A key factor contributing to the rise in human deaths related to malaria and HIV/AIDS is how these diseases can change the hematological parameters in people who are infected with both. Despite the significant effect of malaria and HIV/AIDS on hematological parameters, there are limited data regarding hematological profiles among malaria-HIV coinfected cases. Therefore, this study aimed to determine the hematological profiles of HIV-malaria-coinfected adults receiving highly active antiretroviral therapy at Bonga Gebretsadik Shawo General Hospital. <b>Methods:</b> A hospital-based comparative cross-sectional study was conducted among 196 HIV-infected patients (98 HIV-infected and 98 HIV-malaria coinfected) at Bonga General Hospital from 13 June to 3 November 2022. Five milliliters of venous blood samples were collected to detect parasites, estimate parasite density, measure viral load, and perform a complete blood count. Sociodemographic data were collected using structured questionnaires. Data were analyzed using SPSS Version 25. Descriptive statistics, independent samples <i>t</i>-tests, and Spearman correlation tests were performed. A <i>p</i> value of < 0.05 was set as the cutoff for significance. <b>Results:</b> The study included 196 adults living with HIV. Statistical differences were observed in the mean ± SD values of red blood cells, hemoglobin, and hematocrit (<i>p</i> < 0.05) between HIV-infected and HIV-malaria coinfected study participants. In a total of study participants, significant negative correlations were found between viral load and total white blood cell count, neutrophils, lymphocytes, eosinophils, red blood cells, hemoglobin, hematocrit, mean cell volume, and platelet count. Anemia, leukopenia, and thrombocytopenia were present in 88 (44.9%), 77 (39.3%), and 50 (25.5%) of the 196 participants, respectively. In the HIV-malaria-coinfected group, there was a negative correlation between parasite density and red blood cell count, hemoglobin, hematocrit, and platelets. The prevalence of anemia, leukopenia, and thrombocytopenia among malaria and HIV-coinfected study participants was 60 (61.2%), 43 (43.88%), and 30 (30.6%), respectively. A statistically significant difference (<i>p</i> < 0.001) was observed in the prevalence of anemia between the two groups. <b>Conclusion and Recommendations:</b> The prevalence of anemia was significantly higher in HIV-malaria-coinfected participants than HIV monoinfected paricipants. Mean values of hematological profiles were significantly different in the two groups. Further studies with a larger sample size are needed to support future results.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"3894305"},"PeriodicalIF":0.0,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12393937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144938661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Safety and Efficacy of Venetoclax in Chronic Lymphocytic Leukemia: A Single-Center Comparative Analysis With Randomized Clinical Trials.","authors":"Sophie Thau, Christian Bjørn Poulsen, Morten Kranker Larsen, Lars Møller Pedersen","doi":"10.1155/ah/3910332","DOIUrl":"10.1155/ah/3910332","url":null,"abstract":"<p><p>Treating chronic lymphocytic leukemia (CLL) with the BCL-2 inhibitor venetoclax has shown favorable results in randomized clinical trials (RCTs). Regulatory authorities have recognized the need for also investigating the efficacy and safety of new antineoplastic therapies in real-world (RW) studies with patients often characterized by higher age and comorbidities than patients treated in RCTs. We present a RW single-center study of 112 patients with CLL or small lymphocytic lymphoma (SLL) treated with venetoclax at Zealand University Hospital. A total of 74 patients were treated according to the standard clinical practice and 38 were included in RCTs. No significant differences in efficacy profiles, or safety measures were observed between the two cohorts. Both groups presented overall acceptable tolerability and safety profiles to venetoclax. Moreover, our results suggest that tumor lysis syndrome (TLS) was not a clinical challenge in RW patients even when 6- and 12 h blood samples for TLS were omitted. RW CLL/SLL patients treated outside a clinical trial also had comparable safety and efficacy profiles as reported in the MURANO, CLL13, and CLL14 trials. In conclusion, patients with CLL treated with venetoclax in a RW clinical setting exhibit similar efficacy and safety outcomes to those observed in RCTs.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"3910332"},"PeriodicalIF":0.0,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12381400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144938637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytopenias and Associated Factors in Patients Living With HIV on ARV Treatment in Cameroon: An Analytical Cross-Sectional Study.","authors":"Josué Louokdom Simo, Romaric De Manfouo Tuono, Bendzigho Tatsiane Manewa, Maryline Njopwouo Seuko, Yolande Nathalie Matchein, Claude Tagny Tayou","doi":"10.1155/ah/3328539","DOIUrl":"10.1155/ah/3328539","url":null,"abstract":"<p><p><b>Introduction:</b> Cytopenias are a frequent concern in the management of patients living with HIV/AIDS (PLWHA). The study objective was to determine the burden of anemia and cytopenia among PLWHA on antiretroviral treatment in the Cameroonian context and to identify the associated factors. <b>Methods:</b> We conducted an analytical and cross-sectional study over 4 months. The study population consisted of PLWHAs on ARV treatment at the DREAM Center in Dschang. Blood samples were taken in EDTA and dry tubes. Complete blood counts, CD4 count, ferritin, and serum iron measurements were performed using flow cytometry, ELISA, and spectrophotometry methods. The results were recorded in an Excel spreadsheet and analyzed using SPSS statistical software. <b>Results:</b> 198 PLWHAs on ARV treatment with extremes aged 15-75 years were included in this study, with a sex ratio of 0.48 in favor of women. The frequency of anemia was 32.32%. Triple therapy (3TC + TDF + DLV) was the most commonly used regimen (75.76%). The frequency of anemias was 32.32%, and they were mainly normocytic and normochromic. 8.08% of the population had leukopenia, and 9.09% had thrombocytopenia. Advanced immunodeficiency (CD4 level: 200-500 C/mm³) was identified as a predictive factor for anemia in PLWH in this study (OR = 2.88 [0.82-10.11]; <i>p</i> = 0.097). <b>Conclusion:</b> Cytopenias in general, and anemias, in particular, are very common in patients with HIV/AIDS. These results raise the need for adequate follow-up of the sick population to limit the effects of these cytopenias for a healthier life of patients.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"3328539"},"PeriodicalIF":0.0,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12350016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematological Parameters Among Adult Patients Diagnosed With Type 2 Diabetes Mellitus at Jimma University Medical Center, Jimma, Southwest, Ethiopia.","authors":"Edosa Tadasa, Eman Kemal","doi":"10.1155/ah/2225431","DOIUrl":"10.1155/ah/2225431","url":null,"abstract":"<p><p><b>Background:</b> Diabetes is a significant worldwide health challenge associated with significant metabolic, cellular, and hematological disturbances. Hematological alterations are well-documented complications of diabetes and play a crucial role in the progression of diabetes related pathology. While extensive data exist globally on hematological parameters in type 2 diabetes mellitus (T2DM), specific insights into these parameters and their local determinants within study area remain limited. Therefore, this study aimed to assess the hematological parameters among adult patients diagnosed with T2DM in JUMC at Jimma, Southwest, Ethiopia, 2024. <b>Methods:</b> A total of 200 medical charts of adults with T2DM who registered for follow-up at Jimma University Medical Center were reviewed from December 2023 to February 2024. Data were collected using a data extraction checklist. Bivariate and multivariate logistic regression analyses were performed to identify factors associated with hematologic abnormalities. A <i>p</i> value less than 0.05 indicates statistical significance. <b>Result:</b> The overall prevalence of anemia and leukocytosis in adults with T2DM was 14.0% and 12.0%, respectively. Neutrophilia was the common white blood cell (WBC) abnormality detected in 9.5% of the patients. Besides, thrombocytopenia and thrombocytosis were observed in 2.5% and 1.5% of the patients, respectively. Increasing age 5.28 (95% CI: 1.07-26.1) and duration of diabetes mellitus (≥ 3 years) (AOD = 3.1 (95% CI: 1.02-9.5)) were significantly associated with anemia and leukocytosis, respectively. <b>Conclusion:</b> This study found a prevalence of hematological abnormalities in adults with T2DM, including anemia, elevated WBC count, increased neutrophils, and thrombocytopenia. Anemia was associated with advanced age, while leukocytosis was associated with a longer diabetes duration. Therefore, it is recommended to start regularly screening T2DM patients for hematological abnormalities to improve clinical practice, guide treatment decisions, and develop targeted interventions.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"2225431"},"PeriodicalIF":0.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaemia and Other Haemogram Parameters Associated With Benign Maxillomandibular Odontogenic Lesions.","authors":"Mamadou Diatta, Macoura Gadji, Marie Joseph Diémé, Abdoulaye Keita, Abdou Ba, Bintou Catherine Gassama, Mouhammad Kane, Khadim Seck, Babacar Tamba, Soukeye Dia Tine","doi":"10.1155/ah/7414742","DOIUrl":"10.1155/ah/7414742","url":null,"abstract":"<p><p><b>Introduction:</b> Dental alterations associated with benign odontogenic lesions can alter patients' diet, possibly leading to anaemia. Indeed, cytological studies of fluid contained in benign odontogenic lesions report the presence of blood cells. The aim of this study was, therefore, to investigate anaemia and haemogram parameters in relation to benign odontogenic lesions. <b>Material and Method:</b> We conducted a descriptive cross-sectional study over 24 months in the Odontostomatology Department of the Idrissa Pouye General Hospital in Dakar, Senegal. The selection criteria included all patients who had received treatment for benign odontogenic lesions with an available cell blood count. The collected variables were demographic, clinical and paraclinical, with calculation of inflammation marker ratios. The data were analysed using SPSS 20.0 software, and the Kruskal-Wallis and Fisher tests were also performed for statistical comparison. <b>Results:</b> Of a total of 50 patients, 70% were women. The mean age was 32.6 years, with a mean duration of 41.5 months. Mandibular location was encountered in 76% of the cases. Ameloblastoma and cemento-osseous dysplasia each accounted for 24% of the cases. Anaemia was found in 21 patients, 11 of whom were normocytic normochromic and 8 microcytic hypochromic. Neutropenia was noted in 23 patients. <b>Conclusion:</b> Normocytic normochromic anaemia, microcytic hypochromic anaemia and neutropenia were more common in benign odontogenic lesions. A more detailed study should be undertaken to gain a better understanding of the significance of haemogram parameter variations in benign odontogenic lesions.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"7414742"},"PeriodicalIF":0.0,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12324915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144787985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk-Stratified and Response-Adapted Therapy for Pediatric Hodgkin Lymphoma in Argentina: The GATLA Experience.","authors":"David Veron, Patricia Streitenberger, Mónica Matus, Pedro Negri Aranguren, Alejandra Costa, Daniela Morell, Sergio Terrasa, E Mauricio Castellanos, Pedro de Alarcon, Eduardo Dibar, Mónica Makiya","doi":"10.1155/ah/5453729","DOIUrl":"10.1155/ah/5453729","url":null,"abstract":"<p><p><b>Background:</b> The international cooperation between GATLA and AHOPCA with the support of St. Jude led to the adoption of the OEPA/COPDAC as a strategy to improve outcomes in high risk (HR) patients with HL. This study also includes the ABVD regimen for intermediate risk (IR) and low risk (LR) patients. <b>Methods:</b> Patients were stratified by predefined risk assignment. HR was defined as a disease in stages II B, III B, and IV. Modality treatment: LR: ABVD × 4 ± IFRT (20 Gy); IR: ABVD × 6 ± IFRT (20 Gy); and HR: OEPA-COPDAC + IFRT (20/25 Gy). The staging and response were reviewed in a periodic discussion of presentation of cases in the group. Eligibility for radiotherapy: LR patients in partial response (PR) after 4 ABVD and IR patients in PR after 2 ABVD received IFRT. All HR patients received IFRT at 20 (complete response (CR)) or 25 Gy (PR) depending on the response achieved after the first two OEPA cycles. <b>Results:</b> From November 2012 to June 2022, 203 pediatric patients were enrolled. A total of 171 patients were eligible in this analysis. HR: 98 patients (57.3%), IR: 52 patients (30.4%), and LR: 21 patients (12.3%). More than half of the patients were in stages III and IV and more than half also presented B symptoms. The response evaluation was performed by PET/CT in 147/171 patients (86%). A total of 68/171 patients (40%) did not received radiotherapy. Radiotherapy was omitted in 95% of the LR patients and 70% of the IR patients. The 10-year OS was 95% (90.7-97.6) for the 171 patients and 93% (85.3-96.4) for HR patients. The 10-year EFS was 91% (85.2-94.2) for the 171 patients and 87.8% (79.5-92.9) for HR patients. <b>Conclusion:</b> The international cooperation made it possible to significantly improve the outcomes of patients with advance disease in Argentina compared with our previous experience (7-PHD-96: COPP-ABV × 6 + IFRT Bulky Disease or PR (20/25 Gy): 5yOS: 85%, 5yEFS: 67%), reduce the number of patients who required radiotherapy, and reproduce the European experience for HR patients in a totally different context.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"5453729"},"PeriodicalIF":0.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transition Readiness of Pediatric Sickle Cell Patients to Adult Clinic in a Teaching Hospital, Ghana.","authors":"Aaron Kwasi Nartey, Vivian Paintsil, Isaac Nyanor, Yaa Gyamfua Oppong-Mensah, Evans Xorse Amuzu, Eunice Agyeman Ahmed, Suraj Yawnumah Abubakar, Alex Osei-Akoto","doi":"10.1155/ah/2843974","DOIUrl":"10.1155/ah/2843974","url":null,"abstract":"<p><p><b>Background:</b> Successfully navigating the transition process has received little attention, especially in sub-Saharan Africa. This study assessed the transition readiness of pediatric sickle cell disease (SCD) patients in the Komfo Anokye Teaching Hospital (KATH), Kumasi-Ghana. <b>Methods:</b> A hospital-based cross-sectional study was conducted using a purposive sampling technique to recruit adolescents who were scheduled to be transitioned from the Pediatric to the Adult SCD Clinic at KATH. Two transition assessment tools were adopted and modified to suit our local setting. <b>Findings:</b> Majority of the patients (90%) scored above median mark for the items under the transition self-care importance and confidence and over 50% for most of the items under the disease knowledge and appointment keeping domains. The internal consistencies of the items were over 70% for all the three domains: disease knowledge, medication management, and appointment keeping. In multivariable regression models, older age, female gender, and higher education were associated with higher scores in all the three domains. Also, the sickle cell disease-SS (SCD-SS) status was associated with higher scores in disease knowledge and appointment keeping. Patients staying with both parents were associated with higher scores for the domains but only appointment keeping was statistically significant. Staying with other relations was associated with a lower score for appointment keeping and had significant association for medication management. <b>Conclusion:</b> The study revealed a high transition readiness among pediatric patients. In general, the patients had high confidence transitioning to an adult clinic and the ability to manage their own healthcare. However, patients were hesitant speaking about their SCD status. Staying with both parents was significantly associated with higher scores for appointment keeping. Also, staying with other relations significantly reduced the scores for medication management. We recommend setting up of an adolescent sickle cell support group to help reduce stigmatization and improve health outcomes.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"2843974"},"PeriodicalIF":0.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Bacterial Contamination in Donated Blood for Transfusion Purposes at Kisii Teaching and Referral Hospital.","authors":"Collince O Ogolla, Rodgers N Demba","doi":"10.1155/ah/6934791","DOIUrl":"10.1155/ah/6934791","url":null,"abstract":"<p><p><b>Background:</b> Bacterial contamination of donated blood has been a major public health problem. It poses grave risks to the recipient. <b>Objective:</b> The objective of this study was to determine bacterial contamination in donated blood for transfusion purposes at Kisii Teaching and Referral Hospital. <b>Methodology:</b> This was a cross-sectional study. Sample collection was performed in BD BACTEC culture bottles and analyzed by BD BACTEC Machine FX40 for the presence of bacteria and thereafter subcultured for the positive vials. Biochemical tests were performed followed by confirmation tests with API-20 to identify bacterial presence. Samples negative for bacteria were not subjected to further analysis, and the results were directly recorded. Quality control procedures were performed using known ATCC microorganisms (<i>Staphylococcus aureus</i> [<i>S. aureus</i>] ATCC 25923). The data were entered into Excel and analyzed by SPSS Version 25. <b>Results:</b> The general prevalence of bacterial contamination was 21.3% (23/108). The blood group A positive had the highest contamination rate (10.2%), while the prevalence by age was also higher in the 21-30 years age group (24%). The most commonly isolated organisms were <i>Staphylococcus epidermidis</i> (<i>S. epidermidis</i>) (56.5%), <i>S. aureus</i> (39.1%), <i>Bacillus</i> spp. (30.4%), and <i>Escherichia coli</i> (<i>E. coli</i>) (17.4%). Logistic regression analysis indicated that blood group A positive individuals (OR = 2.5, <i>p</i>=0.02) and the 21-30 years age group (OR = 1.8, <i>p</i>=0.03) were significantly related to contamination at odds. The association of blood group A positive and age 21-30 further augmented this risk (OR = 3.5, <i>p</i>=0.01). <b>Conclusion:</b> <i>S. epidermidis</i>, <i>S. aureus</i>, <i>Bacillus</i> spp. and <i>E. coli</i> were among the isolated and identified bacteria found in donated blood samples among donors at KTRH.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2025 ","pages":"6934791"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144635961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}